{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:30:26Z","timestamp":1792553426182,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005310","name":"Klarman Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005310","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jpsychires.2023.03.031","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T05:39:34Z","timestamp":1679981974000},"page":"364-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2938-2693","authenticated-orcid":false,"given":"Franklin R.","family":"Schneier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Feusner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Wheaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria J.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle","family":"Cornejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akansha Mahesh","family":"Naraindas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Hellerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2023.03.031_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cpr.2016.08.002","article-title":"Suicidality in body dysmorphic disorder (BDD): a systematic review with meta-analysis","volume":"49","author":"Angelakis","year":"2016","journal-title":"Clin. Psychol. Rev."},{"issue":"10","key":"10.1016\/j.jpsychires.2023.03.031_bib2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatr."},{"issue":"7","key":"10.1016\/j.jpsychires.2023.03.031_bib4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatr."},{"issue":"2","key":"10.1016\/j.jpsychires.2023.03.031_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpsychires.2023.03.031_bib7","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jpsychires.2023.03.031_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/YIC.0000000000000342","volume":"36","author":"Castle","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2023.03.031_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatr."},{"issue":"1","key":"10.1016\/j.jpsychires.2023.03.031_bib10","first-page":"102","article-title":"The Brown assessment of beliefs scale: reliability and validity","volume":"155","author":"Eisen","year":"1998","journal-title":"AmJPsychiatry"},{"key":"10.1016\/j.jpsychires.2023.03.031_bib11","first-page":"1","article-title":"Empirically defining treatment response and remission in body dysmorphic disorder","author":"Fernandez de la Cruz","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2023.03.031_bib12","series-title":"Structured Clinical Interview for DSM-5\u2014Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV)","author":"First","year":"2015"},{"issue":"18","key":"10.1016\/j.jpsychires.2023.03.031_bib13","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpsychires.2023.03.031_bib14","series-title":"ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338) Rockville, MD","author":"Guy","year":"1976"},{"key":"10.1016\/j.jpsychires.2023.03.031_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jpsychires.2023.03.031_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-199604000-00011","article-title":"Serotonin, psilocybin, and body dysmorphic disorder: a case report","volume":"16","author":"Hanes","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2023.03.031_bib17","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.neubiorev.2019.12.006","article-title":"Neuropharmacological modulation of the aberrant bodily self through psychedelics","volume":"108","author":"Ho","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"11","key":"10.1016\/j.jpsychires.2023.03.031_bib18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2023.03.031_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1017\/S1092852900016436","article-title":"The prevalence of body dysmorphic disorder in the United States adult population","volume":"13","author":"Koran","year":"2008","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jpsychires.2023.03.031_bib20","article-title":"Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder","author":"Ledwos","year":"2022","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.jpsychires.2023.03.031_bib21","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2023.03.031_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/00048679809062719","article-title":"Dysmorphic concern: prevalence and associations with clinical variables","volume":"32","author":"Oosthuizen","year":"1998","journal-title":"Aust. N. Z. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.03.031_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/02698811211066709","article-title":"Validation of the psychological insight scale: A new scale to assess psychological insight following a psychedelic experience","volume":"36","author":"Peill","year":"2022","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jpsychires.2023.03.031_bib26","first-page":"17","article-title":"A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale","volume":"33","author":"Phillips","year":"1997","journal-title":"Psychopharmacol. Bull."},{"issue":"12","key":"10.1016\/j.jpsychires.2023.03.031_bib28","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.03.031_bib29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1017\/S0033291706007264","article-title":"The prevalence of body dysmorphic disorder: a population-based survey","volume":"36","author":"Rief","year":"2006","journal-title":"Psychol. Med."},{"issue":"Suppl. 20","key":"10.1016\/j.jpsychires.2023.03.031_bib30","first-page":"22","article-title":"The Mini-International Neuro-psychiatric Interview (M.I.N.I.): the development and validation of a structured di-agnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2023.03.031_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.586682","article-title":"Development and evaluation of a therapist training program for psilocybin therapy for treatment-resistant depression in clinical research","volume":"12","author":"Tai","year":"2021","journal-title":"Front. Psychiatr."},{"issue":"6","key":"10.1016\/j.jpsychires.2023.03.031_bib32","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1037\/0022-3514.54.6.1063","article-title":"Development and validation of brief measures of positive and negative affect: the PANAS scales","volume":"54","author":"Watson","year":"1988","journal-title":"J. Personality Soc. Psychol."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395623001504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395623001504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:38:02Z","timestamp":1758368282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395623001504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"alternative-id":["S0022395623001504"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2023.03.031","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2023.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}